Fulgent Genetics (FLGT) Revenue (2015 - 2026)

Fulgent Genetics has reported Revenue for 12 years, with the latest figure at $85.4 million in Q2 2026.

• Quarterly Revenue rose 4.38% year-over-year to $85.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $241.0 million (down 20.52% YoY) and the FY2025 annual result came in at $322.7 million, up 13.83% from the prior year.
• Revenue grew to $85.4 million in Q2 2026 per FLGT's latest filing, from $71.1 million in the prior quarter.
• Over five years, Revenue peaked at $320.3 million in Q1 2022 and troughed at $400000.0 in Q4 2025.
• A 5-year average of $89.1 million and a median of $74.8 million in 2024 frame the typical range for Revenue.
• The widest YoY moves for Revenue: up 17.18% in 2025, down 99.48% in 2025.
• Over 5 years, Revenue stood at $83.6 million in 2022, then declined by 15.66% to $70.5 million in 2023, then gained by 8.1% to $76.2 million in 2024, then plunged by 99.48% to $400000.0 in 2025, then jumped by 21247.25% to $85.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $85.4 million, $71.1 million, and $400000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.